HemaVision® a diagnostic tool for Leukemia screening

• Direct contact technical support
• Find products for your research

Early diagnosis and treatment are critical in improving outcomes for leukemia patients. The earlier treatment can be initiated, the better the chances for successful management of the disease. Rapid and accurate diagnosis, followed by timely treatment, is therefore essential not only for the patients themselves but also for their families. Patients diagnosed early are more likely to respond to targeted therapies and treatments, which significantly improve survival rates and quality of life.

DNA Diagnostic manufactures HemaVision®-28Q, an initial screening tool that screens for 28 different genomic translocations associated with Leukemia. HemaVision® is a series of CE-marked in vitro diagnostic (IVD) tests designed for fast and sensitive detection of chromosomal translocations linked to Leukemia. These tests are a 4-hour RT-qPCR screening method which analyze up to 28 translocations and more than 145 clinically relevant translocation breakpoints in a single test, allowing rapid and accurate

Leukemia screening

The HemaVision® tests utilize total RNA extracted from whole blood or bone marrow as the starting material, ensuring a straightforward and effective process suitable for various clinical settings. Whether used for broad or targeted screening, HemaVision® delivers fast, reliable results to support accurate Leukemia diagnosis and patient care.

Our customers say:

“The HemaVision kit allows us to obtain fast results and to give important information for the diagnosis and prognosis.“

“HemaVision has easier handling through ready to use mixes, faster and more concrete results.”

“The HemaVision workflow is reliable, robust and easy test.”